Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Net Income towards Common Stockholders: 2021-2025

Historic Net Income towards Common Stockholders for Prime Medicine (PRME) over the last 4 years, with Sep 2025 value amounting to -$50.6 million.

  • Prime Medicine's Net Income towards Common Stockholders rose 3.69% to -$50.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.3 million, marking a year-over-year increase of 9.99%. This contributed to the annual value of -$195.9 million for FY2024, which is 1.14% up from last year.
  • Prime Medicine's Net Income towards Common Stockholders amounted to -$50.6 million in Q3 2025, which was up 3.82% from -$52.6 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Net Income towards Common Stockholders ranged from a high of -$22.8 million in Q3 2021 and a low of -$69.3 million during Q4 2021.
  • In the last 3 years, Prime Medicine's Net Income towards Common Stockholders had a median value of -$50.7 million in 2023 and averaged -$49.9 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 41.40% in 2022, then slumped by 61.69% in 2023.
  • Prime Medicine's Net Income towards Common Stockholders (Quarterly) stood at -$69.3 million in 2021, then surged by 41.40% to -$40.6 million in 2022, then tumbled by 61.69% to -$65.6 million in 2023, then soared by 35.60% to -$42.3 million in 2024, then grew by 3.69% to -$50.6 million in 2025.
  • Its Net Income towards Common Stockholders was -$50.6 million in Q3 2025, compared to -$52.6 million in Q2 2025 and -$51.9 million in Q1 2025.